Publications

Cancer cell

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

13-12-2011

Genome research

High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors.

01-12-2011

Hum Mutat: Human mutation

ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes

03-11-2011

BioEssays : news and reviews in molecular, cellular and developmental biology

Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models.

01-09-2011

Gut

Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer

24-08-2011

Nucleic acids research

Computational identification of insertional mutagenesis targets for cancer gene discovery.

01-08-2011

J Clin Invest: The Journal of clinical investigation

Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance

11-07-2011

The Journal of pathology

Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression.

01-05-2011

Disease models & mechanisms

Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice.

01-05-2011

The Journal of pathology

Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system.

01-05-2011

Journal of mammary gland biology and neoplasia

Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer.

01-04-2011

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine

Potential value of color-coded dynamic breast-specific gamma-imaging; comparing (99m)Tc-(V)-DMSA, (99m)Tc-MIBI, and (99m)Tc-HDP in a mouse mammary tumor model.

01-12-2010

BMC cancer

BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.

30-11-2010

Nat Struct Mol Biol.: Nature structural & molecular biology

BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping

14-11-2010

BMC research notes

KC-SMARTR: An R package for detection of statistically significant aberrations in multi-experiment aCGH data.

11-11-2010

Genome Biology

Somatic structural rearrangements in genetically engineered mouse mammary tumors

13-10-2010

Cell cycle (Georgetown, Tex.)

Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.

15-09-2010

Nanotechnology

A self-assembled multimodal complex for combined pre- and intraoperative imaging of the sentinel lymph node.

03-09-2010

BMC cancer

Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.

24-08-2010

Trends Pharmacol Sci.: Trends in pharmacological sciences

Targeting homologous recombination repair defects in cancer

01-08-2010

Nature structural & molecular biology

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.

01-06-2010

Nature cell biology

BRD7 is a candidate tumour suppressor gene required for p53 function.

01-04-2010

Cancer research

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

15-02-2010

Cancer Research

Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach

26-01-2010

Cancer research

Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes.

15-01-2010

Oncogene

Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways.

07-01-2010

PLoS computational biology

Identification of networks of co-occurring, tumor-related DNA copy number changes using a genome-wide scoring approach.

01-01-2010

Clinical cancer research : an official journal of the American Association for Cancer Research

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.

01-01-2010

The Journal of pathology

A tissue reconstitution model to study cancer cell-intrinsic and -extrinsic factors in mammary tumourigenesis.

01-01-2010

Proc Natl Acad Sci U S A: Proceedings of the National Academy of Sciences of the United States of America

Error-prone translesion replication of damaged DNA suppresses skin carcinogenesis by controlling inflammatory hyperplasia

22-12-2009

Methods in molecular biology (Clifton, N.J.)

Studying drug resistance using genetically engineered mouse models for breast cancer.

02-12-2009

Biochimica et biophysica acta

Therapeutic options for triple-negative breast cancers with defective homologous recombination.

01-12-2009

British journal of cancer

Preclinical mouse models for BRCA1-associated breast cancer.

17-11-2009

Breast cancer research : BCR

BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.

28-08-2009

Clinical cancer research: an official journal of the American Association for Cancer Research

CIP2A is associated with human breast cancer aggressivity

15-08-2009

Cancer research

Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.

15-08-2009

Breast cancer research: BRC

It's all in the details: methods in breast development and cancer

14-08-2009

Cancer Research

Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival

01-08-2009

Nature protocols

A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites.

17-06-2009

Current pharmaceutical design

Towards understanding the role of cancer-associated inflammation in chemoresistance.

13-06-2009

Cancer cell

Mammary tumorigenesis through LPA receptor signaling.

02-06-2009

Cancer research

High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

15-04-2009

J Pathol.: The journal of pathology

Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma

01-03-2009

Breast cancer research : BCR

EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.

23-12-2008

Proceedings of the National Academy of Sciences of the United States of America

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

04-11-2008

The EMBO journal

NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin

08-10-2008

Cell cycle (Georgetown, Tex.)

Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility.

01-09-2008

Current biology : CB

Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium.

22-07-2008

Clinical cancer research : an official journal of the American Association for Cancer Research

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

15-06-2008

Cell

Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks.

16-05-2008

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors.

ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes

Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models.

Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer

Computational identification of insertional mutagenesis targets for cancer gene discovery.

Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance

Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression.

Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice.

Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system.

Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer.

Potential value of color-coded dynamic breast-specific gamma-imaging; comparing (99m)Tc-(V)-DMSA, (99m)Tc-MIBI, and (99m)Tc-HDP in a mouse mammary tumor model.

BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.

BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping

KC-SMARTR: An R package for detection of statistically significant aberrations in multi-experiment aCGH data.

Somatic structural rearrangements in genetically engineered mouse mammary tumors

Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.

A self-assembled multimodal complex for combined pre- and intraoperative imaging of the sentinel lymph node.

Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.

Targeting homologous recombination repair defects in cancer

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.

BRD7 is a candidate tumour suppressor gene required for p53 function.

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach

Insertional mutagenesis in mice deficient for p15Ink4b, p16Ink4a, p21Cip1, and p27Kip1 reveals cancer gene interactions and correlations with tumor phenotypes.

Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways.

Identification of networks of co-occurring, tumor-related DNA copy number changes using a genome-wide scoring approach.

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.

A tissue reconstitution model to study cancer cell-intrinsic and -extrinsic factors in mammary tumourigenesis.

Error-prone translesion replication of damaged DNA suppresses skin carcinogenesis by controlling inflammatory hyperplasia

Studying drug resistance using genetically engineered mouse models for breast cancer.

Therapeutic options for triple-negative breast cancers with defective homologous recombination.

Preclinical mouse models for BRCA1-associated breast cancer.

BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.

CIP2A is associated with human breast cancer aggressivity

Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.

It's all in the details: methods in breast development and cancer

Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival

A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites.

Towards understanding the role of cancer-associated inflammation in chemoresistance.

Mammary tumorigenesis through LPA receptor signaling.

High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma

EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin

Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility.

Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium.

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks.

This site uses cookies